Moteur de recherche d’entreprises européennes
Financement de l’UE (6 000 000 €) : Prévention et remédiation de la multimorbidité de l’insuline en Europe Hor01/01/2020 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Prévention et remédiation de la multimorbidité de l’insuline en Europe
PRIME introduces the novel concept of insulin signalling as a key mechanism underlying the multimorbidity of major mental and somatic illnesses. It is well known that aberrant insulin signalling causes high health and socioeconomic burden through its role in diabetes, metabolic syndrome, and obesity. We posit that the impact of ‘insulinopathies’ is still largely underestimated, since insulin multimorbidity also extends to the brain, where altered insulin signalling appears to be implicated in dementias such as Alzheimer disease and – based on our pilot work - in mental illnesses characterized by compulsivity, especially obsessive compulsive disorder and autism. We therefore further posit that insulin multimorbidity evolves throughout life, necessitating a lifespan approach. PRIME brings together a multidisciplinary team to (1) extend our understanding of insulin multimorbidity across the lifespan, (2) understand the causal mechanisms linking somatic and mental insulin-related illnesses, (3) develop tools for early diagnosis, improved clinical care, and prevention of insulin-related lifespan multimorbidity. We will leverage the world’s largest registry, clinical cohort, and population data sets to identify and validate new insulinopathies. Through an interdisciplinary battery of innovative approaches, we will clarify the causal mechanisms linking peripheral and central insulin signalling to body-brain comorbidity, integrating across animal models and studies in humans from molecule to cell, brain, cognition, and behaviour. Our prior evidence enables PRIME to bring the new knowledge to society, based on e.g. repurposing medication and lifestyle interventions (diet/exercise monitored by mHealth assessment), identifying and validating novel drug targets, developing and testing candidate biomarkers, and by improving existing medical guidelines and policy. Furthermore, educational approaches to inform clinicians, patients, and general public will be developed.
| Aarhus Universitet | 399 999 € |
| Biotrial | 246 113 € |
| Biotrial Biometrics | 0,00 € |
| Biotrial Neuroscience | 0,00 € |
| Biotrial Paris | 0,00 € |
| Biotrial Rennes | 0,00 € |
| Biotrial Research | 0,00 € |
| CONCENTRIS RESEARCH MANAGEMENT GmbH | 360 000 € |
| Drug Target ID B.V. | 400 000 € |
| 249 997 € | |
| 148 989 € | |
| Istituto Superiore DI Sanita | 350 000 € |
| JOHANN WOLFGANG GOETHE-UNIVERSITAET FRANKFURT AM MAIN | 549 994 € |
| 160 000 € | |
| Semmelweis Egyetem | 472 500 € |
| 60 000 € | |
| Stichting Radboud Universitair Medisch Centrum | 1 257 414 € |
| 0,00 € | |
| THE European Brain Council Aisbl | 90 000 € |
| UNIVERSITATSKLINIKUM HEIDELBERG | 380 000 € |
| Universiteit Maastricht | 365 000 € |
| Universitetet I Bergen | 350 000 € |
| 159 995 € |
https://cordis.europa.eu/project/id/847879
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.
Les visualisations de "Aarhus Universitet - Financement de l’UE (6 000 000 €) : Prévention et remédiation de la multimorbidité de l’insuline en Europe"
sont mis à disposition par
North Data
et peuvent être réutilisées selon les termes de la licence
Creative Commons CC-BY.
